Exxon Mobil stock is highly leveraged to the price of oil. So, if oil prices recover in 2019, XOM's share price should should spike higher. Read More

The rising incidence of hacking dominates the front pages. We examine cybersecurity firm Bravatek to see if it's a growth play or just another risky fad stock. Read More

Nike is one of the most recognizable brands in the world. The company has faced some stiff competition lately. Will it remain Number One? Read More

This global colossus dominates the thriving management consulting industry. But as the pace of change accelerates, can the company stay on top? Read More

An examination of Therapix Biosciences, its rivals, and a prediction for this micro-cap biotech stock in 2019. Will Therapix prove a winner or loser in the race to develop cannabis-based drugs? Read More

Our review of clinical-stage medical cannabis companies continues, with a fledgling biotech that's generating especially keen interest on Wall Street. Is Cara a future bonanza... or short-term fad? Read More

We spotlight Intec Pharma, its rivals, and whether the stock is overpriced or underpriced. Is this Israel-based biotech on the verge of launching blockbuster new drugs? Read More

An examination of this popular biotech stock, its rivals, whether it's overpriced or underpriced, and a prediction for its prospects in 2019. Read More

Zynerba Pharmaceuticals is a fledgling, small-cap maker of cannabis-based drugs. The stock has attracted considerable media interest, but is it too risky? We sift through the hype to examine the fundamentals. Read More

This maker of cannabis-infused medical treatments is a pre-clinical stage biotech with a small market cap. As such, it's a dangerous stock. But do the opportunities outweigh the risks? Read More